Shaukat Ali, PhD, Senior Director of Scientific Affairs and Technical Marketing, Ascendia Pharmaceuticals, highlights the benefits of the company’s nanotechnologies in supporting formulation development of poorly soluble molecules.
Ascendia Pharma
Advertisement
Articles by Ascendia Pharma
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.
What does Ascendia do? What sets Ascendia apart from its competitors? What is Ascendia's company culture like?
This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.
This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.
Advertisement
Latest Updated Articles
Optimizing Drug Delivery Methods With NanotechnologiesPublished: January 9th 2024 | Updated:
New Opportunities via Novel Formulation TechnologiesPublished: January 9th 2024 | Updated:
Identifying the Right CDMO to Support Biopharma ManufacturingPublished: January 9th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
3
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
4
How AI, Machine Learning, and Large Language Models Enhance Bioanalysis
5
